Tailoring access to high cost, genetically targeted drugs.
Assessment of real cost effectiveness, with data linked to individual health outcomes while protecting patient privacy, is an essential challenge we need to meet.
Hall
Wayne D
WD
Ward
Robyn
R
Liauw
Winston S
WS
Lu
Christine Y
CY
Brien
Jo-anne E
JA
D026683:Advisory Committees; D001315:Australia; D003219:Confidentiality; D003362:Cost-Benefit Analysis; D003659:Decision Making, Organizational; D017277:Drug Approval; D016527:Drug Costs; D005380:Financing, Government; D006297:Health Services Accessibility / Q000191:economics*; D006801:Humans; D007356:Insurance, Pharmaceutical Services / Q000191:economics*; D010597:Pharmacogenetics